Sponsors (27)
The bill funds a rapid FDA study to clarify microplastic exposure and health effects—potentially improving protections and consumer guidance—at the cost of a short timeline that may produce limited findings and trigger future regulatory costs and uncertainty for businesses and consumers.
Children (and other youth) could face lower health risks if the study identifies microplastic exposure pathways and health effects, enabling targeted prevention measures.
Consumers, including people with chronic conditions, may get clearer safety guidance about microplastics in food and water from FDA findings and recommended actions.
Policymakers and taxpayers will receive evidence-based recommendations to inform future regulations or funding priorities addressing microplastics' health risks.
Food and water industries—especially small businesses—could face future compliance costs and higher consumer prices if the study prompts new controls or regulations.
A one-year deadline for the study may limit depth and completeness, increasing the risk of inconclusive or premature findings that lead to inadequate or hasty policy choices affecting many Americans.
If the report leads to stricter controls without clear causal evidence, individuals and businesses could face prolonged uncertainty and burdens during rulemaking and implementation.
Based on analysis of 2 sections of legislative text.
Requires HHS/FDA to study and report to Congress within one year on human health impacts of microplastics in food and water, with recommendations.
Official title: To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to conduct a study, and submit to Congress a report, on the human health impacts of exposure to microplastics in food and water.
Introduced July 17, 2025 by Janelle S. Bynum · Last progress July 17, 2025
Requires the Department of Health and Human Services, through FDA leadership, to study how microplastics in food and drinking water affect human health. The study must identify main exposure pathways and examine effects on children, the endocrine system, cancer, chronic illnesses, reproductive health, and other areas the Secretary chooses, and deliver a report with findings and recommendations to Congress within one year of enactment.